Table 1. Treatment of gastric cancer with ZD6126.

		ZD6126 (100 mg kg−1)
	Control	Weekly	Daily
Body mass (g)±s.e.m.	30.9±0.8	31.3±1.0	29.2±0.7
Tumour volume (mm3)±s.e.m.	440±154	241±39b	79±25a
Tumour mass (g)±s.e.m.	0.5±0.1	0.4±0.1	0.2±0.1b
Incidence of carcinomatosis	10/12 (83.3%)	6/12 (50%)	1/11 (9.1%)c

TMK-1 was injected into the gastric wall on day 0. Therapy with ZD6126, either once a week (weekly) or 5 × per week (daily), was initiated on day 14. Mice were killed on day 38.

^aP<0.002 by Student's t-test.

^bP<0.05 by Student's t-test.

^cP<0.01 by χ² analysis.